I guess my view would be that the whole market was pretty fully-valued, even before Merck came calling for Acceleron, so there wasn't any great case for a wildly-higher offer, beyond the current trading price.
But Farallon Capital tonight proves that this is how markets are made: people will have differing opinions, as to the future value of a given asset. Especially so, in the pharmaceutical R&D and clinical trial pipeline stages.
But my own guess (and it is a guess, not having really done a "deep dive") is that Merck will get to a majority position, one way or another. Said another way, I just don't see someone making a $15 billion or $17 billion topping bid. But. . . we shall see. Onward, smiling. . . .
नमस्ते
No comments:
Post a Comment